In patients treated with anti-PD-1 or anti-PD-L1, however, it is recommended that the appearance of polyuria-polydipsia syndrome, weight loss, or clinical signs evoking ketoacidosis should lead to immediate testing of blood glucose level according to the French Endocrine Society guidance on endocrine side effects of immunotherapy (2019) (22). This evidence concerns the gene PDCD1 and type 2 diabetes mellitus.